The Healthy @Reader's Digest

A Nationwide Recall of 8,500 ADHD Medication Bottles Just Received an Update from the FDA

With an expiration date still more than a year away, here's what the latest details reveal.
GlobalData on MSN

FDA accepts Otsuka’s centanafadine application for ADHD treatment

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...
Becker's Hospital Review

FDA fast-tracks ADHD drug for priority review

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.
Medscape

New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder

termed "ascending dose," was specifically designed to avoid acute tolerance, which is believed to be the cause of the diminished effectiveness of intermediate-acting methylphenidate preparations ...